S&CO Inc. Purchases New Stake in Elanco Animal Health Incorporated $ELAN

S&CO Inc. purchased a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 111,284 shares of the company’s stock, valued at approximately $2,738,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. NewEdge Advisors LLC grew its stake in Elanco Animal Health by 133.7% during the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock worth $25,000 after buying an additional 627 shares during the period. Root Financial Partners LLC raised its stake in shares of Elanco Animal Health by 50.7% in the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock valued at $40,000 after acquiring an additional 592 shares during the period. Uniplan Investment Counsel Inc. acquired a new position in shares of Elanco Animal Health during the 4th quarter valued at $41,000. Torren Management LLC acquired a new position in shares of Elanco Animal Health during the 4th quarter valued at $46,000. Finally, Bessemer Group Inc. boosted its position in Elanco Animal Health by 33.2% during the 1st quarter. Bessemer Group Inc. now owns 2,105 shares of the company’s stock worth $50,000 after purchasing an additional 525 shares during the period. 97.48% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts recently issued reports on ELAN shares. Morgan Stanley increased their price target on Elanco Animal Health from $23.00 to $26.00 and gave the company an “equal weight” rating in a report on Wednesday, July 22nd. Weiss Ratings upgraded Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, July 31st. Piper Sandler reaffirmed an “overweight” rating on shares of Elanco Animal Health in a research report on Monday, June 29th. KeyCorp increased their target price on Elanco Animal Health from $29.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Finally, JPMorgan Chase & Co. raised their target price on Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $29.09.

Elanco Animal Health Price Performance

ELAN opened at $23.64 on Friday. The company has a fifty day simple moving average of $24.56 and a 200 day simple moving average of $24.02. The firm has a market cap of $11.81 billion, a price-to-earnings ratio of -57.65, a PEG ratio of 1.42 and a beta of 1.67. Elanco Animal Health Incorporated has a twelve month low of $17.11 and a twelve month high of $27.98. The company has a current ratio of 2.05, a quick ratio of 1.10 and a debt-to-equity ratio of 0.58.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.07. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The firm had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.31 billion. During the same quarter in the previous year, the business posted $0.26 EPS. The firm’s revenue was up 10.2% compared to the same quarter last year. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Equities research analysts expect that Elanco Animal Health Incorporated will post 1.12 EPS for the current fiscal year.

Insider Transactions at Elanco Animal Health

In other Elanco Animal Health news, Director Michael J. Harrington bought 5,000 shares of the company’s stock in a transaction dated Wednesday, August 12th. The shares were acquired at an average cost of $21.82 per share, with a total value of $109,100.00. Following the completion of the transaction, the director owned 131,451 shares in the company, valued at $2,868,260.82. The trade was a 3.95% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Paul Herendeen purchased 10,000 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The stock was acquired at an average price of $23.68 per share, for a total transaction of $236,800.00. Following the purchase, the director owned 111,687 shares of the company’s stock, valued at approximately $2,644,748.16. This represents a 9.83% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders have acquired 19,200 shares of company stock valued at $442,836. 1.14% of the stock is currently owned by insiders.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.